Plain-English translation of NCT05155137 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Stroke research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The PROMOTE trial is testing a combination pill called a polypill (containing valsartan, amlodipine, and rosuvastatin) to see if it can help prevent stroke and cognitive decline in people aged 50–75 who have not had a stroke before. Some participants will also use a smartphone app called the Stroke Riskometer to help them make healthier lifestyle choices. Researchers want to find out whether the medication alone, or the medication plus lifestyle support, works better than a placebo to reduce stroke and memory problems over three years.
Most strokes happen in people with low to moderate risk, and current prevention strategies aren't catching enough cases. This trial is testing whether giving multiple heart and blood pressure medications together in one pill could be a simpler, more effective way to prevent stroke and cognitive decline in this large group of people.
You likely qualify if…
You likely don't qualify if…
After an initial month on the active medication (to make sure you tolerate it), you will be randomly assigned to one of four groups: the combination pill with the lifestyle app, the combination pill without the app, a placebo pill with the app, or a placebo pill without the app. You'll take your assigned pill daily and use the app (if assigned to that group) to track your health and receive lifestyle coaching. The study lasts three years, and researchers will check your blood pressure and overall health regularly to see whether the medication and lifestyle support help prevent stroke and memory problems.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Brazil